Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China
Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma
China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...
Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA
Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...
Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Lavamed Secures USD 40M in Angel and Series A Financing Rounds
Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Tsingke Biotech Secures RMB 400M Series B Financing for Expansion
Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...